Compare VNRX & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 21.2M |
| IPO Year | 2012 | 2008 |
| Metric | VNRX | NNVC |
|---|---|---|
| Price | $2.47 | $1.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 287.0K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.85 |
| 52 Week High | $2.89 | $2.23 |
| Indicator | VNRX | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 81.68 | 66.99 |
| Support Level | $0.22 | $1.35 |
| Resistance Level | $2.89 | $1.53 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 82.83 | 73.33 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.